Biotech short selling

Revolution Medicines' RAS glue needed fourteen years from funded idea to FDA approval

Moderna's melanoma readout and an FDA approval a week later gave biotech bulls their summer story, though the figure worth underwriting is the calendar behind the RAS drug: money raised in 2012, asset sold in 2018, approval fourteen years on.